-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis announced that the global Phase III clinical program for the once-daily oral administration of the small molecule GLP-1 receptor agonist ASC30 for chronic weight management has completed the first patient administration.

Zhitongcaijing·08/30/2026 10:17:08
Listen to the news
Ascletis announced that the global Phase III clinical program for the once-daily oral administration of the small molecule GLP-1 receptor agonist ASC30 for chronic weight management has completed the first patient administration.